Reports on Chronic Kidney Disease Findings from San Luigi Gonzaga Hospital Provide New Insights [Effect of Phospholipid Curcumin Meriva(R) On Liver Histology and Kidney Disease In Nonalcoholic Steatohepatitis a Randomized, Double-blind,...].

A recent study conducted at San Luigi Gonzaga Hospital in Turin, Italy, has found that the administration of phospholipid curcumin (Meriva) for 72 weeks improved liver histology, kidney disease, and metabolic profile in patients with nonalcoholic steatohepatitis (NASH). The study involved 52 biopsy-proven NASH patients who were randomized to receive either Meriva or a placebo. The results showed that Meriva treatment led to a higher rate of NASH resolution, fibrosis improvement, and regression of liver fibrosis compared to the placebo. Additionally, Meriva improved renal function, glucose levels, lipid profile, and inflammatory markers. The study concluded that Meriva administration was safe and well-tolerated in NASH patients. [Extracted from the article]

Copyright of Gastroenterology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)